Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive Disorder

ClinicalTrials.gov ID: NCT06058039

Public ClinicalTrials.gov record NCT06058039. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 12, 2026, 7:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This randomized, double-blind, placebo-controlled, multicenter study will evaluate the effects of NMRA-335140 (formerly BTRX-335140) on symptoms of depression in participants with Major Depressive Disorder (MDD). The study design consists of a Screening Period (up to 35 days), and a 6-week Treatment Period (during which participants will receive either NMRA-335140 or placebo). At the completion of the 6-week Treatment Period, participants who complete the study, provide informed consent, and meet the eligibility criteria may enter an open-label extension study (NMRA-335140-501).

Study identification

NCT ID
NCT06058039
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Neumora Therapeutics, Inc.
Industry
Enrollment
422 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 20, 2023
Primary completion
May 3, 2026
Completion
Jun 10, 2026
Last update posted
Jul 5, 2026

2023 – 2026

United States locations

U.S. sites
34
U.S. states
11
U.S. cities
30
Facility City State ZIP Site status
Neumora Investigator Site Cerritos California 90703
Neumora Investigator Site Irvine California 92614
Neumora Investigator Site Long Beach California 90807
Neumora Investigator Site San Diego California 92103
Neumora Investigator Site San Francisco California 94107
Neumora Investigator Site New Haven Connecticut 06520
Neumora Investigator Site Brandon Florida 33511
Neumora Investigator Site Hialeah Florida 33012
Neumora Investigator Site Hialeah Florida 33016
Neumora Investigator Site Jacksonville Florida 32256
Neumora Investigator Site Miami Florida 33143
Neumora Investigator Site Miami Florida 33165
Neumora Investigator site Miami Florida 33174
Neumora Investigator Site Miami Beach Florida 33140
Neumora Investigator site Miami Springs Florida 33166
Neumora Investigator Site Palm Bay Florida 32905
Neumora Investigator Site Pembroke Pines Florida 33024
Neumora Investigator Site Pompano Beach Florida 33060
Neumora Investigator Site Saint Augustine Florida 32086
Neumora Investigator Site Atlanta Georgia 30328
Neumora Investigator Site Decatur Georgia 30030
Neumora Investigator Site Savannah Georgia 31405
Neumora Investigator Site Springfield Massachusetts 01103
Neumora Investigator Site St Louis Missouri 63141
Neumora Investigator Site Omaha Nebraska 68112
Neumora Investigator Site Berlin New Jersey 08009
Neumora Investigator Site New York New York 10029
Neumora Investigator Site New York New York 10036
Neumora Investigator Site Staten Island New York 10310
Neumora Investigator Site Charlotte North Carolina 28211
Neumora Investigator Site Austin Texas 78759
Neumora Investigator Site DeSoto Texas 75115
Neumora Investigator Site Fort Worth Texas 76104
Neumora Investigator Site Plano Texas 75093

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 37 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06058039, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 5, 2026 · Synced Sep 12, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06058039 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →